Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DHP2302R1 and DHP2302R2 in Healthy Adults
NCT06318845Phase 1Completed
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of clopidogrel and tegoprazan in peptic ulcer disease (PUD) and thrombosis (6 arms), sponsored by Daehwa Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at Day 9 and Maximum Plasma Concentration at Day 9. Started Mar 2024; status: completed.
02
Drugs
clopidogreltegoprazan
03
Conditions
peptic ulcer disease (PUD)thrombosis
Beyond the preview
Go deeper on NCT06318845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06318845.